Phase I clinical trial combining imatinib mesylate and IL-2 HLA-DR+ NK cell levels correlate with disease outcome

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Chaput, Nathalie ^a,b   Flament, Caroline ^a,b   Locher, Clara ^a,b,c   Desbois, Mélanie ^a,c   Rey, Annie ^a   Rusakiewicz, Sylvie ^a,b   Poirier Colame, Vichnou ^a,b   Pautier, Patricia ^a   Le Cesne, Axel ^a   Soria, Jean Charles ^a,c   Paci, Angelo ^a   Rosenzwajg, Michelle ^b,d,e,f   Klatzmann, David ^b,d,e,f   Eggermont, Alexander ^a,c   Robert, Caroline ^a   Zitvogel, Laurence ^a,b,c  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e CNRS   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Cancer; Imatinib mesylate; Innate immunity; Interleukin 2; Melanoma; Nk cells; Regulatory t cells

Indexed keywords

2 [2 METHYL 5 [4 (1 PIPERAZINYLMETHYL)BENZAMIDO]ANILINO] 4 (3 PYRIDYL)PYRIMIDINE; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; HLA DR ANTIGEN; IMATINIB; INTERLEUKIN 2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; DRUG EFFICACY; HUMAN; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAXIMUM TOLERATED DOSE; NATURAL KILLER CELL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; UPREGULATION;

EID: 84886944930     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23080     Document Type: Article

References (43)

1. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-8; PMID:16960692; http://dx.doi.org/10.1007/s00262-006-0225-8.
2. Mignot G, Ullrich E, Bonmort M, Ménard C, Apetoh L, Taieb J, et al. The critical role of IL-15 in the antitumor effects mediated by the combination therapy imatinib and IL-2. J Immunol 2008; 180:6477-83; PMID:18453565.
3. Taieb J, Chaput N, Ménard C, Apetoh L, Ullrich E, Bonmort M, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12:214-9; PMID:16444265; http://dx.doi. org/10.1038/nm1356.
4. Taieb J, Chaput N, Schartz N, Roux S, Novault S, Ménard C, et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol 2006; 176:2722-9; PMID:16493027.
5. Emadi A, Jones RJ, Brodsky RA. Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009; 6:638-47; PMID:19786984; http://dx.doi. org/10.1038/nrclinonc.2009.146.
6. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011; 33:369-83; PMID:21611872; http://dx.doi.org/10.1007/s00281-011-0245-0.
7. Schiavoni G, Sistigu A, Valentini M, Mattei F, Sestili P, Spadaro F, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788.
8. van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAILdependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 2009; 4:e6982; PMID:19746156; http://dx.doi.org/10.1371/journal.pone.0006982.
9. Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, et al. Cyclophosphamide induces differentiation of Th17 cells in cancer patients. Cancer Res 2011; 71:661-5; PMID:21148486; http://dx.doi. org/10.1158/0008-5472.CAN-10-1259.
10. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91:163-8; PMID:9923858; http://dx.doi.org/10.1093/jnci/91.2.163.
11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6; PMID:8616716; http://dx.doi.org/10.1038/nm0596-561.
12. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-7; PMID:11287972; http://dx.doi.org/10.1056/NEJM200104053441401.
13. Buchdunger E, Zimmermann J, Mett H, Meyer T, Müller M, Druker BJ, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996; 56:100-4; PMID:8548747.
14. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-6; PMID:11287975; http://dx.doi.org/10.1056/NEJM200104053441404.
15. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-80; PMID:12181401; http://dx.doi.org/10.1056/NEJMoa020461.
16. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26:626-32; PMID:18235122; http://dx.doi.org/10.1200/JCO.2007.13.4452.
17. Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST). Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol 2010; 28:1247-53; PMID:20124181; http://dx.doi.org/10.1200/JCO.2009.24.2099.
18. Larmonier N, Janikashvili N, LaCasse CJ, Larmonier CB, Cantrell J, Situ E, et al. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors. J Immunol 2008; 181:6955-63; PMID:18981115.
19. Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, et al. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med 2011; 17:1094-100; PMID:21873989; http://dx.doi. org/10.1038/nm.2438.
20. Borg C, Terme M, Taïeb J, Ménard C, Flament C, Robert C, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114:379-88; PMID:15286804.
21. Ménard C, Blay JY, Borg C, Michiels S, Ghiringhelli F, Robert C, et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res 2009; 69:3563-9; PMID:19351841; http://dx.doi.org/10.1158/0008-5472.CAN-08-3807.
22. Ullrich E, Bonmort M, Mignot G, Jacobs B, Bosisio D, Sozzani S, et al. Trans-presentation of IL-15 dictates IFN-producing killer dendritic cells effector functions. J Immunol 2008; 180:7887-97; PMID:18523252.
23. Ghiringhelli F, Ménard C, Terme M, Flament C, Taieb J, Chaput N, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med 2005; 202:1075-85; PMID:16230475; http://dx.doi. org/10.1084/jem.20051511.
24. Marchetti G, Meroni L, Molteni C, Bandera A, Franzetti F, Galli M, et al. Interleukin-2 immunotherapy exerts a differential effect on CD4 and CD8 T cell dynamics. AIDS 2004; 18:211-6; PMID:15075538; http://dx.doi.org/10.1097/00002030-200401230-00010.
25. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med 2011; 365:2055-66; PMID:22129252; http://dx.doi. org/10.1056/NEJMoa1108188.
26. Saadoun D, Rosenzwajg M, Joly F, Six A, Carrat F, Thibault V, et al. Regulatory T-cell responses to lowdose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011; 365:2067-77; PMID:22129253; http://dx.doi.org/10.1056/NEJMoa1105143.
27. Matos ME, Schnier GS, Beecher MS, Ashman LK, William DE, Caligiuri MA. Expression of a functional c-kit receptor on a subset of natural killer cells. J Exp Med 1993; 178:1079-84; PMID:7688785; http://dx.doi.org/10.1084/jem.178.3.1079.
28. Shah MH, Freud AG, Benson DM Jr., Ferkitich AK, Dezube BJ, Bernstein ZP, et al. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 2006; 12:3993-6; PMID:16818697; http://dx.doi. org/10.1158/1078-0432.CCR-06-0268.
29. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, et al. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005; 115:2139-48; PMID:16025158; http://dx.doi. org/10.1172/JCI23196.
30. Lévy Y, Thiébaut R, Gougeon ML, Molina JM, Weiss L, Girard PM, et al.; ILIADE Study Group. Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV. AIDS 2012; 26:711-20; PMID:22301410; http://dx.doi.org/10.1097/QAD.0b013e3283519214.
31. Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005; 115:1839-47; PMID:15937547; http://dx.doi. org/10.1172/JCI24307.
32. De Paoli P, Zanussi S, Caggiari L, Bortolin MT, D'Andrea M, Simonelli C, et al. Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2. J Clin Immunol 1999; 19:317-25; PMID:10535609; http://dx.doi.org/10.1023/A:1020547826191.
33. Caligiuri MA, Murray C, Robertson MJ, Wang E, Cochran K, Cameron C, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993; 91:123-32; PMID:7678599; http://dx.doi.org/10.1172/JCI116161.
34. Hänninen EL, Körfer A, Hadam M, Schneekloth C, Dallmann I, Menzel T, et al. Biological monitoring of low-dose interleukin 2 in humans: soluble interleukin 2 receptors, cytokines, and cell surface phenotypes. Cancer Res 1991; 51:6312-6; PMID:1933892.
35. Meropol NJ, Barresi GM, Fehniger TA, Hitt J, Franklin M, Caligiuri MA. Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing. Cancer Immunol Immunother 1998; 46:318-26; PMID:9756416; http://dx.doi. org/10.1007/s002620050493.
36. Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, et al. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity. Clin Cancer Res 1996; 2:669-77; PMID:9816217.
37. Bernstein ZP, Porter MM, Gould M, Lipman B, Bluman EM, Stewart CC, et al. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood 1995; 86:3287-94; PMID:7579429.
38. Chen LL, Chen X, Choi H, Sang H, Chen LC, Zhang H, et al. Exploiting antitumor immunity to overcome relapse and improve remission duration. Cancer Immunol Immunother 2012; 61:1113-24; PMID:22198309; http://dx.doi.org/10.1007/s00262-011-1185-1.
39. Evans JH, Horowitz A, Mehrabi M, Wise EL, Pease JE, Riley EM, et al. A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG. Eur J Immunol 2011; 41:1924-33; PMID:21491418; http://dx.doi. org/10.1002/eji.201041180.
40. Lanier LL, Buck DW, Rhodes L, Ding A, Evans E, Barney C, et al. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen. J Exp Med 1988; 167:1572-85; PMID:3259252; http://dx.doi. org/10.1084/jem.167.5.1572.
41. Welner RS, Pelayo R, Garrett KP, Chen X, Perry SS, Sun XH, et al. Interferon-producing killer dendritic cells (IKDCs) arise via a unique differentiation pathway from primitive c-kitHiCD62L+ lymphoid progenitors. Blood 2007; 109:4825-931; PMID:17317852; http://dx.doi.org/10.1182/blood-2006-08-043810.
42. Guimont-Desrochers F, Boucher G, Dong Z, Dupuis M, Veillette A, Lesage S. Redefining interferon-producing killer dendritic cells as a novel intermediate in NK-cell differentiation. Blood 2012; 119:4349-57; PMID:22353997; http://dx.doi.org/10.1182/blood-2011-11-395954.
43. Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, et al. Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity. Nat Med 2006; 12:207-13; PMID:16444266; http://dx.doi.org/10.1038/nm1352.